» Articles » PMID: 18216058

Impact of Chronic Airflow Obstruction in a Working Population

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2008 Jan 25
PMID 18216058
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Data on the individual and collective impact of chronic airflow obstruction at a population level are scarce. In a nationwide survey, dyspnoea, quality of life and missed working days were compared between subjects with and without spirometrically diagnosed chronic airflow obstruction. Subjects aged > or =45 yrs were recruited in French health prevention centres (n = 5,008). Results of pre-bronchodilator spirometry and questionnaires (European Community Respiratory Health Survey-derived questionnaire and European quality of life five-dimension questionnaire) were collected. Adequate datasets were available for 4,764 subjects aged 60+/-10 yrs (only 2% were aged > or =80 yrs). The prevalence of airflow obstruction (forced expiratory volume in one second/forced vital capacity of <0.70) was 7.5%. The vast majority (93.9%) of cases had not been diagnosed previously. Health status was significantly influenced by dyspnoea. Both were associated with the number of missed working days. Despite mild-to-moderate severity, subjects with chronic airflow obstruction exhibited more dyspnoea, poorer quality of life and higher numbers of missed working days (mean 6.71 versus 1.45 days.patient(-1).yr(-1) in patients without airflow obstruction, for the population with no known heart or lung disease). In conclusion, even mild-to-moderate airflow obstruction is associated with an impaired health status, which represents an additional argument in favour of early detection in chronic obstructive pulmonary disease.

Citing Articles

Twelve barriers to COPD diagnosis in France: a comparative qualitative study.

Roucoux G, Scanferla E, Delorme M, Fraticelli L, Kiakouama Maleka L, Nocent-Ejnaini C BMJ Open Respir Res. 2025; 12(1).

PMID: 39843356 PMC: 11759880. DOI: 10.1136/bmjresp-2024-002708.


Quality Standard Position Statements for Health System Policy Changes in Diagnosis and Management of COPD: A Global Perspective.

Bhutani M, Price D, Winders T, Worth H, Gruffydd-Jones K, Tal-Singer R Adv Ther. 2022; 39(6):2302-2322.

PMID: 35482251 PMC: 9047462. DOI: 10.1007/s12325-022-02137-x.


Pooled Cohort Probability Score for Subclinical Airflow Obstruction.

Bhatt S, Balte P, Schwartz J, Jaeger B, Cassano P, Chaves P Ann Am Thorac Soc. 2022; 19(8):1294-1304.

PMID: 35176216 PMC: 9353954. DOI: 10.1513/AnnalsATS.202109-1020OC.


Underdiagnosis of obstructive lung disease: findings from the French CONSTANCES cohort.

Delmas M, Benezet L, Ribet C, Iwatsubo Y, Zins M, Nadif R BMC Pulm Med. 2021; 21(1):319.

PMID: 34649556 PMC: 8518215. DOI: 10.1186/s12890-021-01688-z.


Targeted therapy in eosinophilic chronic obstructive pulmonary disease.

Fieldes M, Bourguignon C, Assou S, Nasri A, Fort A, Vachier I ERJ Open Res. 2021; 7(2).

PMID: 33855061 PMC: 8039900. DOI: 10.1183/23120541.00437-2020.